Abstract
Infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites or fungi remain the top major cause of death across the world, particularly in low income countries, and may be transmitted from person to person, or from insects or animals. In general, infectious diseases may be treated with antimicrobial agents including antibiotics, antiviral, antifungal or antiparasitic medications. The therapeutic application of antimicrobial drugs in the 20th century substantially contributed to the global control of infectious diseases worldwide. However, pathogenic microbes have evolved various mechanisms to render the antimicrobial drugs less effective. This has resulted in an increasing number of people infected with pathogenic microbes that are resistant to antimicrobial drugs, and in some cases leading to untreatable infections. Therefore, new antimicrobial drugs are urgently needed to prevent possible recurrence and emergence of previously treatable infectious diseases. In the past decades, protein kinase inhibitors have become an attractive area in the development of novel antimicrobial drugs. In the current review, we will describe the recent efforts in the development of microbial and host protein kinase-targeting inhibitors as potential antimicrobial drugs against HIV, tuberculosis and malaria.
Keywords: Protein kinase inhibitors, antimicrobial drugs, infectious diseases, tuberculosis, malaria, AIDS.
Current Pharmaceutical Design
Title:Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV
Volume: 23 Issue: 29
Author(s): Yong Cheng*, Jeffrey S. Schorey, Cheng-Cai Zhang and Xuejuan Tan
Affiliation:
- Department of Biology, University of Notre Dame, 131 Galvin Life Science Center, Notre Dame, Indiana 46556,United States
Keywords: Protein kinase inhibitors, antimicrobial drugs, infectious diseases, tuberculosis, malaria, AIDS.
Abstract: Infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites or fungi remain the top major cause of death across the world, particularly in low income countries, and may be transmitted from person to person, or from insects or animals. In general, infectious diseases may be treated with antimicrobial agents including antibiotics, antiviral, antifungal or antiparasitic medications. The therapeutic application of antimicrobial drugs in the 20th century substantially contributed to the global control of infectious diseases worldwide. However, pathogenic microbes have evolved various mechanisms to render the antimicrobial drugs less effective. This has resulted in an increasing number of people infected with pathogenic microbes that are resistant to antimicrobial drugs, and in some cases leading to untreatable infections. Therefore, new antimicrobial drugs are urgently needed to prevent possible recurrence and emergence of previously treatable infectious diseases. In the past decades, protein kinase inhibitors have become an attractive area in the development of novel antimicrobial drugs. In the current review, we will describe the recent efforts in the development of microbial and host protein kinase-targeting inhibitors as potential antimicrobial drugs against HIV, tuberculosis and malaria.
Export Options
About this article
Cite this article as:
Cheng Yong *, Schorey S. Jeffrey, Zhang Cheng-Cai and Tan Xuejuan, Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV, Current Pharmaceutical Design 2017; 23 (29) . https://dx.doi.org/10.2174/1381612823666170612122429
DOI https://dx.doi.org/10.2174/1381612823666170612122429 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF α Signaling Beholds Thalidomide Saga: A Review of Mechanistic Role of TNF-α Signaling Under Thalidomide
Current Topics in Medicinal Chemistry Antimicrobial Peptides and their Pore/Ion Channel Properties in Neutralization of Pathogenic Microbes
Current Topics in Medicinal Chemistry Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Multi-Target-Directed Ligands as Innovative Tools to Combat Trypanosomatid Diseases
Current Topics in Medicinal Chemistry Antitubercular Drug Development: Current Status and Research Strategies
Mini-Reviews in Medicinal Chemistry Articulating A Rights-Based Approach to HIV Treatment and Prevention Interventions
Current HIV Research Structure of the Cytoplasmic Segment of Histidine Kinase Receptor QseC: A Key Player in Bacterial Virulence
Protein & Peptide Letters Recent Developments in Azole Compounds as Antitubercular Agent
Mini-Reviews in Organic Chemistry Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission
Recent Patents on CNS Drug Discovery (Discontinued) New Anti-Tuberculosis Drugs with Novel Mechanisms of Action
Current Medicinal Chemistry Three-Dimensional Quantitative Structure-Activity Relationships for a Large Series of Potent Antitubercular Agents
Letters in Drug Design & Discovery Recent Trends on the Development of Machine Learning Approaches for the Prediction of Lysine Acetylation Sites
Current Medicinal Chemistry Potential Triazole-based Molecules for the Treatment of Neglected Diseases
Current Medicinal Chemistry Online Heart-Cutting Liquid Chromatographic Analysis of Linezolid in Human Serum
Current Pharmaceutical Analysis Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology LYS70 of E. coli Quinolinate Phosphoribosyltransferase Is Protected from Chemical Modification by Formation of an Inhibitor Complex.
Protein & Peptide Letters Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Synthesis and Antimicrobial Activity of Nitroalkenyl Arenes
Anti-Infective Agents